CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

December 19, 2022 by CN Bio

Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services. Former CEO, Dr David Hughes, appointed to Scientific Advisory Board.


CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

Paul Brooks |

Paul’s appointment signifies the next stage of CN Bio’s commercial development. He will be focused on driving the Company’s global expansion plans, to reach new customers and create value for shareholders. Having joined the Company as Chief Business Officer in May 2022, Paul was responsible for shaping CN Bio’s commercial business, expansion strategy and overseeing accelerated growth of the Company’s PhysioMimix™ OOC range of MPS, consumables, kits and services. In this time, CN Bio also doubled the laboratory space dedicated to its contract research services, in response to rising demand for the Company’s OOC expertise by pharma and biotech companies.

With over 25 years of experience in the Life Science sector, Paul is an experienced C-suite level executive; prior to joining CN Bio, he was Head of Business Operations & Managing Director for PerkinElmer’s Horizon Discovery, where he led the strategic and operational transformation of its business units. Throughout his career, Paul has supported successful growth across a broad range of companies, including Head of Discovery Research Services & General Manager at Sigma-Aldrich (now Merck KGaA), and as Chief Commercial Officer & Executive Director and Board member at Oxford Genetics, driving its transformation from start-up company to commercialisation. Paul completed his PhD in Molecular Biology from the University of Manchester Institute of Science and Technology and holds an MBA from Nottingham Business School.

As part of the Scientific Advisory Board, CN Bio will continue to benefit from Dr David Hughes’ domain expertise and extensive technical bioengineering background. In this consultative role, Dr Hughes will remain involved in the future development of CN Bio’s product and service portfolio.


Dr Paul Brooks, CEO at CN Bio, said: “I would like to thank David for his leadership of CN Bio through a transformational time, and I look forward to working with him as we begin to fully exploit our incredible innovation engine. I am honoured to be appointed CEO at a pivotal time in the Company’s, and the industry’s, evolution, as the value of well-characterised microphysiological systems is increasingly recognised to revolutionise therapeutic programmes. As we enter 2023, CN Bio is well positioned to build upon its successes so far and enter this exciting next stage of commercial growth and expansion.”


Dr David Hughes, previously CEO, CN Bio, commented: “Since joining the team, Paul has been a driving force for initiating the next phase of CN Bio’s development. His breadth of industry experience, paired with extensive technical expertise, is a huge asset to the Company as CEO, and I am confident that he will successfully continue our mission to transform drug discovery. My sincere thanks go to the team, who I have worked alongside for 12 years, and I now look forward to supporting CN Bio’s innovation and growth in an advisory role.”

Category iconPress releases

Primary Sidebar

Other recent news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022
  • Pharmacokinetics in mice… or a microfluidic device! August 3, 2022
  • CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities July 19, 2022

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023